TIN Ny Teknik vs Avanza Healthcare

TIN Ny Teknik vs Avanza Healthcare

1. TIN Ny Teknik

  • Security

    TIN Ny Teknik A

  • Fee

    1.50%

  • ISIN

    SE0012193019

  • Holdings

    10

2. Avanza Healthcare

  • Security

    Avanza Healthcare by Samuelsson & Hult

  • Fee

    1.25%

  • ISIN

    SE0019912502

  • Holdings

    25

Fund Holdings

We have information about 10 holdings in TIN Ny Teknik, where the largest holding is Surgical Science (7.39), followed by Novo Nordisk (5.98) and ChemoMetec (5.92). In comparison with Avanza Healthcare, we have 28 holdings where UnitedHealth is the largest holding (8.79), followed by Eli Lilly (7.45) and Novo Nordisk (6).

All Holdings

Here we compare the holdings in TIN Ny Teknik and Avanza Healthcare.

TIN Ny Teknik Avanza Healthcare
1. Surgical Science Sweden AB
Sweden
7.39 %
1. UnitedHealth Group Inc
USA
8.79 %
2. Novo Nordisk B
Denmark
5.98 %
2. Eli Lilly and Co
USA
7.45 %
3. ChemoMetec
Denmark
5.92 %
3. Novo Nordisk B
Denmark
6 %
4. Paradox Interactive AB
Sweden
5.85 %
4. Merck & Co Inc
Germany
5.71 %
5. Qt Group Plc
Finland
5.12 %
5. AstraZeneca
Sweden UK
4.46 %
6. Epidemic Sound Holdings AB
Sweden
5.11 %
6. Thermo Fisher Scientific Inc
4.44 %
7. BioGaia B
Sweden
5.06 %
7. Amgen Inc
3.69 %
8. Fortnox AB
Sweden
5.02 %
8. Boston Scientific Corp
3.36 %
9. Evolution Gaming Group AB
Sweden
4.6 %
9. Stryker Corp
3.29 %
10. Sectra B
Sweden
4.45 %
10. Novartis AG
Switzerland
3.02 %
- 11. Cencora Inc
USA
2.91 %
- 12. Vertex Pharmaceuticals Inc
2.87 %
- 13. Regeneron Pharmaceuticals Inc
2.84 %
- 14. AbbVie Inc
USA
2.83 %
- 15. Gilead Sciences Inc
USA
2.73 %
- 16. Takeda Pharmaceutical Co Ltd
Japan
2.56 %
- 17. Dexcom Inc
USA
2.01 %
- 18. Daiichi Sankyo Co Ltd
Japan
1.76 %
- 19. IQVIA Inc
1.73 %
- 20. Terumo Corp
1.27 %
- 21. Edwards Lifesciences Corp
1.22 %
- 22. Neurocrine Biosciences Inc
1.17 %
- 23. Pfizer Inc
USA
1.16 %
- 24. Sartorius AG PRF Perpetual EUR
1.13 %
- 25. Ionis Pharmaceuticals Inc
1.08 %

The list of fund holdings was last updated on April 17, 2025.